TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Prostatype Genomics AB
Closing information (x1000 EUR)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 |
| Turnover |
17
|
122
|
61 |
| Financial expenses |
146
|
198
|
36 |
| Earnings before taxes |
-3,574
|
-3,734
|
-2,614 |
| EBITDA |
-3,384
|
-3,368
|
-2,407 |
| Total assets |
3,654
|
4,436
|
2,781 |
| Current assets |
1,029
|
2,335
|
1,273 |
| Current liabilities |
740
|
2,206
|
389 |
| Equity capital |
2,914
|
2,224
|
2,350 |
| - share capital |
58
|
646
|
123 |
| Employees (average) |
6
|
7
|
6 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 |
| Solvency |
79.7%
|
50.1%
|
84.5% |
| Turnover per employee |
3
|
17
|
10 |
| Profit as a percentage of turnover |
-21023.5%
|
-3060.7%
|
-4285.2% |
| Return on assets (ROA) |
-93.8%
|
-79.7%
|
-92.7% |
| Current ratio |
139.1%
|
105.8%
|
327.2% |
| Return on equity (ROE) |
-122.6%
|
-167.9%
|
-111.2% |
| Change turnover |
-101
|
61
|
60 |
| Change turnover % | -85% | 6730% | |
| Chg. No. of employees |
-1
|
1
|
1 |
| Chg. No. of employees % | -14% | 20% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.